Surgery – Truss – Pad
Patent
1990-09-05
1992-06-09
Rosenbaum, C. Fred
Surgery
Truss
Pad
128898, 436 64, 435 4, 435 32, 424 9, A61B 1000
Patent
active
051198274
ABSTRACT:
The present invention involves a method for early detection of developing tamoxifen resistance in breast cancer. Tamoxifen is the drug of choice for hormonal therapy of a first recurrence of breast cancer, but its use is always associated eventually with emergence of resistant tumors. Whereas initial treatment is usually followed by tumor regression, resistant tumors may actually resume growth under continued tamoxifen treatment. Because such growth may actually be augmented by the tamoxifen, it is essential to identify the onset of resistance as early as possible so alternative therapy may be promptly instituted.
REFERENCES:
patent: 4806464 (1991-02-01), Spelsberg
patent: 4919937 (1990-04-01), Mauvais-Jarvis et al.
patent: 5023234 (1991-06-01), Labrie
patent: 5030417 (1991-07-01), Spelsberg
CA114(7):55296d, Structure-Function Relationships of Hydroxylated Metabolites of Tamoxifen that Control the Proliferation of Estrogen-Responsive T47D Breast Cancer Cells In Vitro, Murphy et al., 1990.
CA108(23):198501d Ligand Interaction of the Estrogen Receptor to Program Antiestrogen Action: A Study With Non-Steroidal Compounds In-Vitro, Craig et al., 1988.
W. E. Simon et al., "Development of Resistance to Tamoxifen and Progestins in Human Mammary Cancer", Proc. Int. Congr. Chemother., 13th, vol. 18, 270/1-270/4, 1983.
Jordan, et al., Endocrinology, 122(4):1449-1454, 1988, "Ligand Interaction at the Estrogen Receptor to Program Antiestrogen Action: A Study With Nonsteroidal Compounds in Vitro".
Armstrong et al., J. Chromat., 414:192-96, 1987, "Separation of Tamoxifen Geometric Isomers and Metabolites by Bonded-Phase .beta.-Cyclodextrin Chromatography".
Katzenellenbogen et al., J. Steroid Biochem., 22(5):589-96, 1985, "Facile Geometric Isomerization of Phenolic Non-Steroidal Estrogens and Antiestrogens: Limitations to the Interpretation of Experiments Characterizing the Activity of Individual Isomers".
Katzenellenbogen et al., Cancer Res., 44:112-19, 1984, "Bioactivities, Estrogen Receptor Interactions, and Plasminogen Activator-Inducing Activities of Tamoxifen and Hydroxy-Tamoxifen Isomers in MCF-7 Human Breast Cancer Cells".
Robertson et al., J. Steroid Biochem., 16:1-13, 1982, "Tamoxifen Antiestrogens, a Comparison of the Activity, Pharmacokinetics, and Metabolic Activation of the Cis and Trans Isomers of Tamoxifen".
Jordan et al., Endocrinology, 108(4):1353-61, 1981, "Geometric Isomers of Substituted Triphenylethylenes and Antiestrogen Action".
Jordan et al., Cancer Treatment Reports, 60(10):1409-19, 1976, "Antiestrogenic and Antitumor Properties of Tamoxifen in Laboratory Animals".
Fromson et al., Xenobiotica, 3(11):711-14, 1973, "The Metabolism of Tamoxifen (I.C.I. 46,474) Part II: in Female Patients".
Fromson et al., Xenobiotica, 3(11):693-704, 1973, "The Metabolism of Tamoxifen (I.C.I. 46,474) Part I: in Laboratory Animals".
Terenius, Acta Endocrinologica, 66:431-47, 1971, "Structure-Activity Relationships of Anti-Oestrogens with Regard to Interaction with 17.beta.-Oestradiol in the Mouse Uterus and Vagina".
Harper et al., J. Reprod. Fert., 13:101-119, 1967, "A New Derivative of Triphenylethylene: Effect on Implantation and Mode of Action in Rats".
De Gregorio Michael W.
Osborne C. Kent
Board of Regents , The University of Texas System
Polutta Mark O.
Rosenbaum C. Fred
Yale University
LandOfFree
Mechanisms of antiestrogen resistance in breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mechanisms of antiestrogen resistance in breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mechanisms of antiestrogen resistance in breast cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1798212